ClinicalTrials.gg
CompletedNCT01436162Updated Jun 9, 2021Results posted

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

A Phase 3 interventional study of Antidepressant + SPD489 (Lisdexamfetamine dimesylate ) and Antidepressant + Placebo in Major Depressive Disorder, sponsored by Shire. Completed at 101 sites in 11 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-06-09.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,105
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies in Depressive Disorder, Major by Takeda — 1 open to participants now, 1 under way, 1 of them phase 3. Depressive Disorder, Major · Takeda.

Enrollment
5th of 24
1,105 · median 580
Started
2011
with 5 others
Phase 3
16 of 26
1 open now
Registered
15th of 26
by date

Among the 26 studies in Depressive Disorder, Major by Takeda, this one is the 5th largest by enrollment of the 24 interventional ones that give a count, is one of 6 that started in 2011, is one of 16 in phase 3, and was the 15th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 26 studies in Depressive Disorder, Major by Takeda is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Depressive Disorder, Major by Takeda, or all of them as a file.
02

Study summary

This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms. Eligible patients will remain on their antidepressant but will be randomized to either receive supplemental SPD489 or placebo (i.e. sugar pill). The purpose of this study is to help answer the following questions:

  • How safe is SPD489 for the supplemental treatment of depression and what are the side effects that might be related to it?
  • Can supplemental SPD489 help patients who still have residual depression symptoms while taking an antidepressant?
  • How much SPD489 should be given to patients with depression who are also taking an antidepressant?
  • How does SPD489 compare to placebo in depressed patients who are also taking an antidepressant?
03

Conditions studied

  • Major Depressive Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is able to provide written, personally signed, and dated to participate in the study before completing any study-related procedures.
  2. Subject is between 18 and 65 years of age.
  3. Subject has a primary diagnosis of non-psychotic MDD.
  4. Subject has a MADRS total score >/=24.
  5. Subject is willing and has an understanding and ability to fully comply with study procedures and restrictions defined in this protocol.
  6. Subject, who is female, must have a negative serum beta human chorionic gonadotropin (B-HCG) pregnancy test and a negative urine pregnancy test and agrees to comply with any applicable requirements of the protocol.
  7. Subject is able to swallow a capsule.

Exclusion criteria

Exclusion Criteria:

  1. Subject whose current episode of MDD has not responded to an adequate treatment regimen with 2 or more approved single antidepressant agents.
  2. Subject who has a lifetime history of treatment resistant depression, defined as having not responded to adequate treatment with 2 or more treatment regimens.
  3. Subject has a current co-morbid psychiatric disorder that is either controlled with medications prohibited in this study or is uncontrolled and associated with significant symptoms.
  4. Subject has been hospitalized (within the last 12 months) for their current MDD episode.
  5. Subject has a current or lifetime history of attention-deficit/hyperactivity disorder (ADHD).
  6. Subject has a first degree relative that has been diagnosed with bipolar I disorder.
  7. Subject has a recent history (within the last 6 months) of suspected substance abuse or dependence disorder.
  8. Subject is considered a suicide risk, has previously made a suicide attempt within the past 3 years, or is currently demonstrating active suicidal ideation.
  9. Subject has a concurrent chronic or acute illness or unstable medical condition.
  10. Subject has a history of seizures (other than infantile febrile seizures), any tic disorder, or a current diagnosis and/or a known family history of Tourette's Disorder, serious neurological disease, history of significant head trauma, dementia, cerebrovascular disease, Parkinson's disease, or intracranial lesions.
  11. Subject has known history of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems.
  12. Subject has a history of thyroid disorder that has not been stabilized on thyroid medication or treatment within 3 months prior to the Screening Visit.
  13. Subject has a known family history of sudden cardiac death or ventricular arrhythmia.
  14. Subject has glaucoma.
  15. Subject has any or clinical laboratory abnormalities.
  16. Subject has a history of moderate to severe hypertension.
  17. Current use of any other medications (including over-the-counter [OTC], herbal or homeopathic preparations) that have central nervous system effects.
  18. Subject has the potential need to initiate or modify frequency of psychotherapy or to continue or initiate other treatments for depression, outside of those allowed in this protocol.
  19. Subject has had electroconvulsive therapy (ECT) for the current depressive episode 3 months prior to the Lead-in Baseline Visit.
  20. The subject has a known or suspected intolerance or to the product.
  21. The subject has a known or suspected intolerance, hypersensitivity, or to their assigned antidepressant treatments (escitalopram oxalate, sertraline HCl, venlafaxine HCl extended release, or duloxetine HCl).
  22. Subject has a positive urine drug result.
  23. Subject has a (BMI) of \<18.5 or >40.
  24. Subject is female and is pregnant or nursing.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,105 participants (actual)

Study arms

  • Experimental
    Antidepressant + SPD489

    Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate )

  • Placebo comparator
    Antidepressant + Placebo

    Drug: Antidepressant + Placebo

Interventions

  • DrugAntidepressant + SPD489 (Lisdexamfetamine dimesylate )

    Drug page: Lisdexamfetamine

    Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + SPD489 (oral, 20, 30, 50 or 70 mg, once daily) for 8 weeks

    Also known as: Vyvanse

  • DrugAntidepressant + Placebo

    Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at 8 Weeks

    MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.

    Time frame: 8 weeks

Secondary outcomes

  1. Mean Change From Baseline in Sheehan Disability Scale (SDS) Total Score at 8 Weeks

    Designed to evaluate the extent to which illness symptoms impact a subject's life in 3 areas: work/school, social, and family/home. Each area is scored on a scale from 0 (no impairment) to 10 (highly impaired) with a total score ranging from 0 (unimpaired) to 30 (highly impaired). Lower scores translate into less impairment.

    Time frame: 8 weeks

  2. Percentage of Participants Achieving a 25% Response on the MADRS

    The percentage of subjects who achieved a 25% response (i.e. ≥25% reduction in MADRS total score from the Lead-in Baseline, Visit 2).

    Time frame: Up to 8 weeks

  3. Percentage of Participants Achieving a 50% Response on the MADRS

    The percentage of subjects who achieved a 50% response (i.e. ≥50% reduction in MADRS total score from the Lead-in Baseline, Visit 2).

    Time frame: Up to 8 weeks

  4. Percent of Participants Achieving Remission on the MADRS

    MADRS remission was defined as a MADRS total score of ≤10.

    Time frame: Up to 8 weeks

  5. Mean Change From Baseline Over Time in MADRS Total Score

    MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.

    Time frame: Up to 8 weeks

  6. Mean Change From Baseline in Abbreviated Brief Assessment of Cognition Affective Disorders (ABAC-A) Composite T-Scores

    The ABAC-A is a rater-administered series of activities designed to be sensitive to the critical cognitive deficits in affective disorders and schizophrenia. There are 6 subtests of the ABAC-A: List Learning (verbal memory); Digit Sequencing Task (working memory); Token Motor Task (motor speed); Verbal Fluency; Symbol Coding (attention and processing speed); and Tower of London Test (executive functions). The ABAC-A Composite T-score change from Augmentation Baseline Visit (Visit 8; Week 8) at Visit 14/Early Termination (ET) (Week 16/ET) was analyzed.

    Time frame: up to 8 weeks

  7. Mean Change From Baseline in the Short Form-12 Health Survey V2 (SF-12V2)

    Total score ranges from 0 (lowest level of health) - 100 (highest level of health) on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability (i.e. a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability). Higher scores are associated with better quality of life.

    Time frame: Up to 8 weeks

  8. Mean Change in Sexual Functioning Questionnaire - 14 Item Scale (CSFQ-14) Total Score Male

    The CSFQ-14 is a short-form interview/questionnaire that measures illness- and medication-related changes in sexual functioning. A 5-point Likert scale is used ranging from 1 (never) to 5 (always). The CSFQ-14 total score can range from 14 to 70, with lower scores being associated with worsened sexual functioning.

    Time frame: Up to 8 weeks

  9. Mean Change in Sexual Functioning Questionnaire - 14 Item Scale (CSFQ-14) Total Score Female

    The CSFQ-14 is a short-form interview/questionnaire that measures illness- and medication-related changes in sexual functioning. A 5-point Likert scale is used ranging from 1 (never) to 5 (always). The CSFQ-14 total score can range from 14 to 70, with lower scores being associated with worsened sexual functioning.

    Time frame: Up to 8 weeks

  10. Clinical Global Impressions - Global Improvement (CGI-I)

    Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.

    Time frame: Up to 8 weeks

  11. Mean Change From Baseline in the Multidimensional Assessment of Fatigue (MAF) Global Fatigue Index (GFI)

    MAF contains 16 items scored on a scale from 1 (not at all) to 10 (a great deal). Answers are converted to a Global Fatigue Index with total scores ranging from 1 (no fatigue) to 50 (severe fatigue). Lower scores indicate less fatigue.

    Time frame: Up to 8 weeks

  12. Columbia Suicide Severity Rating Scale (C-SSRS)

    C-SSRS is a semi-structured interview that captures the occurence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale.

    Time frame: Up to 8 weeks

  13. Amphetamine Cessation Symptom Assessment (ACSA) - Total Aggregate Score

    ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity.

    Time frame: 8 weeks

07

Results

Posted Nov 7, 2014

Participant flow

Single-blind Lead-in Phase
Participant flow — Single-blind Lead-in Phase
MilestoneAntidepressant + Single-blind PlaceboAntidepressant + Double-blind SPD489Antidepressant + Double-blind Placebo
Started110500
Completed82300
Not completed28200
Withdrew: Adverse event2600
Withdrew: Protocol violation2400
Withdrew: Withdrawal by subject6900
Withdrew: Lost to follow-up4300
Withdrew: Met bp or pulse withdrawal criteria1300
Withdrew: Other10700
Randomized Phase
Participant flow — Randomized Phase
MilestoneAntidepressant + Single-blind PlaceboAntidepressant + Double-blind SPD489Antidepressant + Double-blind Placebo
Started397212214
Completed353181189
Not completed443125
Withdrew: Adverse event156
Withdrew: Protocol violation442
Withdrew: Withdrawal by subject1698
Withdrew: Lost to follow-up1754
Withdrew: Lack of efficacy011
Withdrew: Met bp or pulse withdrawal criteria420
Withdrew: Other254

Outcome measures

PrimaryMean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at 8 Weeks

MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.

Time frame:
8 weeks
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at 8 Weeks
units on a scaleAntidepressant + SPD489Antidepressant + Placebo
Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at 8 Weeks-7.3 (-8.6 to -6.0)-6.8 (-8.1 to -5.5)
Statistical analysis
  • Antidepressant + SPD489 vs Antidepressant + Placebo · Mixed-effects Model for Repeat Measures · p = 0.583 · Mean difference (final values): -0.5 · 95% CI -2.3 to 1.3
SecondaryMean Change From Baseline in Sheehan Disability Scale (SDS) Total Score at 8 Weeks

Designed to evaluate the extent to which illness symptoms impact a subject's life in 3 areas: work/school, social, and family/home. Each area is scored on a scale from 0 (no impairment) to 10 (highly impaired) with a total score ranging from 0 (unimpaired) to 30 (highly impaired). Lower scores translate into less impairment.

Time frame:
8 weeks
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline in Sheehan Disability Scale (SDS) Total Score at 8 Weeks
units on a scaleAntidepressant + SPD489Antidepressant + Placebo
Mean Change From Baseline in Sheehan Disability Scale (SDS) Total Score at 8 Weeks-4.9 (-5.8 to -4.0)-4.3 (-5.2 to -3.4)
Statistical analysis
  • Antidepressant + SPD489 vs Antidepressant + Placebo · Mixed-effects Model for Repeat Measures · p = 0.354 · Mean difference (final values): -0.6 · 95% CI -1.9 to 0.7
SecondaryPercentage of Participants Achieving a 25% Response on the MADRS

The percentage of subjects who achieved a 25% response (i.e. ≥25% reduction in MADRS total score from the Lead-in Baseline, Visit 2).

Time frame:
Up to 8 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a 25% Response on the MADRS
percentage of participantsAntidepressant + SPD489Antidepressant + Placebo
Percentage of Participants Achieving a 25% Response on the MADRS68.974.2
SecondaryPercentage of Participants Achieving a 50% Response on the MADRS

The percentage of subjects who achieved a 50% response (i.e. ≥50% reduction in MADRS total score from the Lead-in Baseline, Visit 2).

Time frame:
Up to 8 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a 50% Response on the MADRS
percentage of participantsAntidepressant + SPD489Antidepressant + Placebo
Percentage of Participants Achieving a 50% Response on the MADRS41.637.1
SecondaryPercent of Participants Achieving Remission on the MADRS

MADRS remission was defined as a MADRS total score of ≤10.

Time frame:
Up to 8 weeks
Reported as:
Number · percentage of participants
Percent of Participants Achieving Remission on the MADRS
percentage of participantsAntidepressant + SPD489Antidepressant + Placebo
Percent of Participants Achieving Remission on the MADRS23.017.8
SecondaryMean Change From Baseline Over Time in MADRS Total Score

MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.

Time frame:
Up to 8 weeks
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline Over Time in MADRS Total Score
units on a scaleAntidepressant + SPD489Antidepressant + Placebo
Week 9 (Visit 9)-2.9 (-3.9 to -2.0)-2.1 (-3.0 to -1.1)
Week 10 (Visit 10)-4.4 (-5.5 to -3.3)-4.3 (-5.4 to -3.2)
Week 11 (Visit 11)-5.9 (-7.1 to -4.7)-5.0 (-6.2 to -3.8)
Week 12 (Visit 12)-6.3 (-7.6 to -5.1)-5.3 (-6.5 to -4.1)
Week 14 (Visit 13)-6.9 (-8.2 to -5.5)-6.4 (-7.7 to -5.1)
Week 16 (Visit 14)-7.3 (-8.6 to -6.0)-6.8 (-8.1 to -5.5)
SecondaryMean Change From Baseline in Abbreviated Brief Assessment of Cognition Affective Disorders (ABAC-A) Composite T-Scores

The ABAC-A is a rater-administered series of activities designed to be sensitive to the critical cognitive deficits in affective disorders and schizophrenia. There are 6 subtests of the ABAC-A: List Learning (verbal memory); Digit Sequencing Task (working memory); Token Motor Task (motor speed); Verbal Fluency; Symbol Coding (attention and processing speed); and Tower of London Test (executive functions). The ABAC-A Composite T-score change from Augmentation Baseline Visit (Visit 8; Week 8) at Visit 14/Early Termination (ET) (Week 16/ET) was analyzed.

Time frame:
up to 8 weeks
Reported as:
Least squares mean · t-score
Mean Change From Baseline in Abbreviated Brief Assessment of Cognition Affective Disorders (ABAC-A) Composite T-Scores
t-scoreAntidepressant + SPD489Antidepressant + Placebo
Mean Change From Baseline in Abbreviated Brief Assessment of Cognition Affective Disorders (ABAC-A) Composite T-Scores3.0 (2.1 to 4.0)2.5 (1.5 to 3.5)
SecondaryMean Change From Baseline in the Short Form-12 Health Survey V2 (SF-12V2)

Total score ranges from 0 (lowest level of health) - 100 (highest level of health) on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability (i.e. a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability). Higher scores are associated with better quality of life.

Time frame:
Up to 8 weeks
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline in the Short Form-12 Health Survey V2 (SF-12V2)
units on a scaleAntidepressant + SPD489Antidepressant + Placebo
Physical1.07 (0.04 to 2.10)0.90 (-0.11 to 1.91)
Mental6.63 (5.03 to 8.23)5.16 (3.60 to 6.73)
SecondaryMean Change in Sexual Functioning Questionnaire - 14 Item Scale (CSFQ-14) Total Score Male

The CSFQ-14 is a short-form interview/questionnaire that measures illness- and medication-related changes in sexual functioning. A 5-point Likert scale is used ranging from 1 (never) to 5 (always). The CSFQ-14 total score can range from 14 to 70, with lower scores being associated with worsened sexual functioning.

Time frame:
Up to 8 weeks
Reported as:
Mean · units on a scale
Mean Change in Sexual Functioning Questionnaire - 14 Item Scale (CSFQ-14) Total Score Male
units on a scaleAntidepressant + SPD489Antidepressant + Placebo
Mean Change in Sexual Functioning Questionnaire - 14 Item Scale (CSFQ-14) Total Score Male2.1 ± 6.221.0 ± 6.02
SecondaryMean Change in Sexual Functioning Questionnaire - 14 Item Scale (CSFQ-14) Total Score Female

The CSFQ-14 is a short-form interview/questionnaire that measures illness- and medication-related changes in sexual functioning. A 5-point Likert scale is used ranging from 1 (never) to 5 (always). The CSFQ-14 total score can range from 14 to 70, with lower scores being associated with worsened sexual functioning.

Time frame:
Up to 8 weeks
Reported as:
Mean · units on a scale
Mean Change in Sexual Functioning Questionnaire - 14 Item Scale (CSFQ-14) Total Score Female
units on a scaleAntidepressant + SPD489Antidepressant + Placebo
Mean Change in Sexual Functioning Questionnaire - 14 Item Scale (CSFQ-14) Total Score Female3.0 ± 7.111.9 ± 5.82
SecondaryClinical Global Impressions - Global Improvement (CGI-I)

Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.

Time frame:
Up to 8 weeks
Reported as:
Number · percentage of participants
Clinical Global Impressions - Global Improvement (CGI-I)
percentage of participantsAntidepressant + SPD489Antidepressant + Placebo
Improved56.953.5
Not Improved43.146.5
Not Assessed00
SecondaryMean Change From Baseline in the Multidimensional Assessment of Fatigue (MAF) Global Fatigue Index (GFI)

MAF contains 16 items scored on a scale from 1 (not at all) to 10 (a great deal). Answers are converted to a Global Fatigue Index with total scores ranging from 1 (no fatigue) to 50 (severe fatigue). Lower scores indicate less fatigue.

Time frame:
Up to 8 weeks
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline in the Multidimensional Assessment of Fatigue (MAF) Global Fatigue Index (GFI)
units on a scaleAntidepressant + SPD489Antidepressant + Placebo
Mean Change From Baseline in the Multidimensional Assessment of Fatigue (MAF) Global Fatigue Index (GFI)-6.6 ± 0.74-4.4 ± 0.73
SecondaryColumbia Suicide Severity Rating Scale (C-SSRS)

C-SSRS is a semi-structured interview that captures the occurence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale.

Time frame:
Up to 8 weeks
Reported as:
Number · percentage of participants
Columbia Suicide Severity Rating Scale (C-SSRS)
percentage of participantsAntidepressant + SPD489Antidepressant + Placebo
≥1 positive suicidal ideation9.09.4
≥1 suicidal attempt00.5
SecondaryAmphetamine Cessation Symptom Assessment (ACSA) - Total Aggregate Score

ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity.

Time frame:
8 weeks
Reported as:
Mean · Score
Amphetamine Cessation Symptom Assessment (ACSA) - Total Aggregate Score
ScoreAntidepressant + SPD489Antidepressant + Placebo
Amphetamine Cessation Symptom Assessment (ACSA) - Total Aggregate Score17.0 ± 10.8017.2 ± 10.56

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SPD489—1/211 (0.5%)72/211 (34.1%)
Placebo—1/213 (0.5%)46/213 (21.6%)
Most frequent serious events
Most frequent serious events
EventSPD489Placebo
Accelerated hypertensionVascular disorders1/2110/213
Suicidal ideationPsychiatric disorders0/2111/213
Most frequent other events
Most frequent other events
EventSPD489Placebo
Dry mouthGastrointestinal disorders25/2116/213
HeadacheNervous system disorders25/21116/213
NasopharyngitisInfections and infestations14/21119/213
Decreased appetiteMetabolism and nutrition disorders13/2115/213
InsomniaPsychiatric disorders11/2117/213
HyperhidrosisSkin and subcutaneous tissue disorders11/2111/213

Baseline characteristics

Safety Analysis Set: All subjects who took at least 1 dose of randomized investigational product and who had at least 1 safety assessment.

Age, Continuous
Age, Continuous(Years)Antidepressant + Double-blind SPD489Antidepressant + Double-blind PlaceboTotal
Mean42 ± 11.6342.6 ± 11.4142.3 ± 11.51
Age, Customized
Age, Customized(Participants)Antidepressant + Double-blind SPD489Antidepressant + Double-blind PlaceboTotal
18-55 years181184365
56-65 years302959
Sex: Female, Male
Sex: Female, Male(Participants)Antidepressant + Double-blind SPD489Antidepressant + Double-blind PlaceboTotal
Female141143284
Male7070140
08

Study locations

101 sites
  • ResearchOne, Inc.
    Scottsdale, Arizona 85251, United States
  • K&S Professional Research Services, LLC
    Little Rock, Arkansas 72201, United States
  • ATP Clinical Research, Inc.
    Costa Mesa, California 92626, United States
  • Diligent Clinical Trials
    Downey, California 90241, United States
  • Synergy Clinical Reserach Center of Escondido
    Escondido, California 92025, United States
  • Pacific Research Partners, LLC
    Oakland, California 94612, United States
  • Anderson Clinical Research
    Redlands, California 92374, United States
  • BreakThrough Clinical Trials, LLC
    San Bernardino, California 92408, United States
  • MCB Clinical Research Centers
    Colorado Springs, Colorado 80910, United States
  • Florida Clinical Research Center, LLC
    Bradenton, Florida 34201, United States
  • Scientific Clinical Research, Inc.
    North Miami, Florida 33161, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32806, United States
  • Comprehensive NeuroScience, Inc.
    Saint Petersburg, Florida 33716, United States
  • Janus Center for Psychiatric Research
    West Palm Beach, Florida 33407, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30308, United States
  • Atlanta Institute of Medicine & Research
    Atlanta, Georgia 30328, United States
  • Pedia Research
    Newburgh, Indiana 47630, United States
  • Heartland Research Associates
    Wichita, Kansas 67207, United States
  • Louisiana Clinical Research, LLC
    Shreveport, Louisiana 71115, United States
  • Comprehensive Psychiatric Associates
    Gladstone, Missouri 64118, United States
  • The Center for Pharmaceutical Research
    Kansas City, Missouri 64114, United States
  • Mercy Health Research
    Saint Louis, Missouri 63141, United States
  • Bio Behavioral Health
    Toms River, New Jersey 08755, United States
  • Brooklyn Medical Institute
    Brooklyn, New York 11214, United States
  • Medical & Behavioral Health Research, PC
    New York, New York 10023, United States
  • Midwest Clinical Research Center
    Dayton, Ohio 45417, United States
  • North Star Medical Research, LLC
    Middleburg Heights, Ohio 44130, United States
  • Sooner Clinical Research
    Oklahoma City, Oklahoma 73112, United States
  • Lehigh Center for Clinical Research
    Allentown, Pennsylvania 18104, United States
  • Belmont Center for Comprehensive Treatment
    Philadelphia, Pennsylvania 19131, United States
  • Medical University South Carolina Anxiety Disorder Program
    North Charleston, South Carolina 29406, United States
  • Psychiatric Consultants, PC
    Franklin, Tennessee 37067, United States
  • Research Strategies of Memphis, LLC
    Memphis, Tennessee 38119, United States
  • KRK Medical Research
    Dallas, Texas 75230, United States
  • Future Search Trials of Dallas, LP
    Dallas, Texas 75231, United States
  • Clinical Trials of Texas, Inc.
    San Antonio, Texas 78229, United States
  • Dr Lieven De Weirdt
    Sint Niklaas, 9100, Belgium
  • Saint Anne s.r.o.
    Brno, 60200, Czechia
  • Psychiatricka ambulance
    Brno, 615 00, Czechia
  • Medicana s.r.o.
    Horovice, 268 01, Czechia
  • Psychiatrie s.r.o.
    Kutna Hora, 284 01, Czechia
  • Bialbi s.r.o.
    Litomerice, 41201, Czechia
  • Clintrial s.r.o.
    Prague 10, 10000, Czechia
  • Psychiatry Trial s.r.o.
    Prague 5, 15800, Czechia
  • Prague Medical Services s.r.o.
    Prague 6, 160 00, Czechia
  • Ricany s.r.o.
    Ricany, 251 01, Czechia
  • Parnu Hospital, Psychiatric Clinic
    Parnu, 80012, Estonia
  • North Estonia Medical Centre Foundation Psychiatry Clinic
    Tallinn, 10614, Estonia
  • Marienthal Psychiatry and Psychology Center
    Tallinn, 10617, Estonia
  • Jaanson & Laane OU
    Tartu, 50406, Estonia
  • Tartu University Hospital Psychiatric Clinic
    Tartu, 50417, Estonia
  • ARTES Psykiatrinen Palvelukeskus Oy
    Helsinki, 00100, Finland
  • Satucon Oy
    Kuopio, 70100, Finland
  • Satakunnan Psykiatripalveiu Oy at Mentoria Oy
    Tampere, 26200, Finland
  • Puutorin Psykiatripalvelu
    Turku, 20100, Finland
  • Gemeinschafstpraxis für Neurologie und Psychiatrie, Psychotherapie
    Achim, 28832, Germany
  • Private Praxis Dr. Jana Thomsen
    Berlin, 10245, Germany
  • emovis GmbH
    Berlin, 10629, Germany
  • Alexander Schulze, MD
    Berlin, 13156, Germany
  • Private Practice Drs. Bitter/Schumann
    Bochum, 44805, Germany
  • University Hospital Carl Gustav Carus
    Dresden, 01307, Germany
  • ZSL Zentrum fuer medizinische Studien in Leipzig
    Leipzig, 04157, Germany
  • Studienzentrum Muenchen
    Muenchen, 80333, Germany
  • Universitaetsklinikum Munster
    Muenster, 48149, Germany
  • Studienzentrum Klinikum Nuernberg
    Nuernberg, 90419, Germany
  • Somni bene GmbH
    Schwerin, 19053, Germany
  • Private Practice: Eugen Schlegel
    Siegen, 57072, Germany
  • Studiezentrum Nord-West
    Westerstede, 26655, Germany
  • Medizinisches Studienzentrum Wuerzburg
    Wuerzburg, 97070, Germany
  • Semmelweis Univ. Dept.of Psychiatry
    Budapest, 1083, Hungary
  • Debrecent Egyetem Orvos es Egeszsegtudomanyl Centrum Pszichiatrai
    Debrecen, H-4032, Hungary
  • Santha Kalman Mentalis Egeszsegkozpont es Szakkorhaz
    Nagykallo, 4320, Hungary
  • Josa Andras Teaching Hospital
    Nyiregyhaza, H-4400, Hungary
  • Pecsi Tudomanyegyeiem Pszichiatriai es Pszichoterapias Klinika
    Sziget, Hungary
  • Prywatne Gabinety Lekarskie "Promedicus"
    Bialystok, 15-879, Poland
  • NZOZ Centrum Kultury, Higieny i Zdrowia Psychicznego
    Bydgoszcz, 85-156, Poland
  • Zespol Opieki Zdrowotnej w Chelmnie
    Chelmno, 86-200, Poland
  • Centrum Badan Klinicznuch Pl-House sp. z.o.o.
    Gdansk, 80-546, Poland
  • Klinika Chorob Psychicznych i Zaburzen Nerwicowych
    Gdansk, 80-952, Poland
  • Centrum Psychiatrii i Psychoterapli
    Gorlice, 38-300, Poland
  • NZOZ Syntonia, Poradnia Zdrowia Psychicznego
    Kielce, 25-317, Poland
  • Osrodek Badafi Klinicznych Prof dr hab n med Meszek Szczepanski Prywatna Praktyka Lekarska
    Lublin, 20-022, Poland
  • Samodzielny Publiczny Zespol Zakladow Opieki Zdrowotnej w Zurominie
    Zuromin, 09-300, Poland
  • Spitatul Clinic Judetean de Urgenta Arad, Clinica de Psihiatrie
    Arad, 310022, Romania
  • Stefi-Dent SRL
    Botosani, 710107, Romania
  • Spitalui Clinic de Psihiatrie "Prof. Dr. Alexandru Obregia" Sectia Clinica Psihiatrie I
    Bucharest, 041915, Romania
  • Crucea Alba
    Oradea, 410163, Romania
  • Lorentina 2201 SRL
    Targoviste, 130081, Romania
  • Spitalul Clinic Judetean Mures
    Targu Mures, 540095, Romania
  • Cape Trial Centre
    Bellville, Cape Town 7530, South Africa
  • Flexivest Fourteen Research Centre
    Bellville, Cape Town 7530, South Africa
  • Private Practice - Gerta Brink
    Johannesburg, Gauten 2195, South Africa
  • Somerset West Clinical Research
    Somerset West, Western Cape, South Africa
  • Vista Clinic
    Centurion, 0046, South Africa
  • George Medi Clinic Extension
    George, 6529, South Africa
  • SU/ Affektiva 1
    Göteborg, 41685, Sweden
  • ProbarE i Lund AB
    Lund, 22222, Sweden
  • Ekdahl Medical AB
    Malmo, 21153, Sweden
  • INM Psykiatrisk Mottagning
    Malmo, 21153, Sweden
  • Medinstructor Lippitz AB
    Stockholm, 11486, Sweden

Showing the first 100 of 101 sites across 11 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Richards C, McIntyre RS, Weisler R, Sambunaris A, Brawman-Mintzer O, Gao J, Geibel B, Dauphin M, Madhoo M. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies. J Affect Disord. 2016 Dec;206:151-160. doi: 10.1016/j.jad.2016.07.006. Epub 2016 Jul 5. PubMed 27474961 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2011 to primary completion in Dec 2013, 25 months.

Results were first posted in Nov 2014, 10 months after primary completion. A results delay was requested in Aug 2014.

Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 25 months is close to that.

Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2011
First posted
Sep 19, 2011
StartActual
Oct 19, 2011
Primary completionActual
Dec 10, 2013
CompletionActual
Dec 10, 2013
Results delay requested
Aug 20, 2014
Results first posted
Nov 7, 2014
Last update
Jun 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01436162
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Sep 19, 2011
Start date
Oct 19, 2011
Primary completion
Dec 10, 2013
Completion
Dec 10, 2013
Results posted
Nov 7, 2014
Last update
Jun 9, 2021

Study contacts

Study Director
study director · Takeda
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisdexamfetamine

Start the discussion